NEW YORK (GenomeWeb News) — Molecular Diagnostics company SensiGen has received a $300,000 investment from Delaware Crossing Investor Group, a mid-Atlantic-based group of angel investors.
 
SensiGen, based in Ann Arbor, Mich., said it plans to use the funds to develop and sell its AttoSense molecular diagnostic technology, which blends PCR and mass spectrometry to locate biomarkers.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.